What clinical trials has Iclusig (ponatinib) been studied in?
Iclusig (ponatinib) was evaluated in clinical trials as a targeted treatment for certain patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), including people whose disease had not responded to earlier tyrosine kinase inhibitors or who developed resistance or intolerance.
Which populations did the main Iclusig trials enroll?
Across Iclusig’s development, trials focused on patients with:
- CML (including chronic phase, accelerated phase, or blast phase) after failure of prior therapies
- Ph+ ALL after failure of prior therapies
These are the groups where ponatinib’s kinase-targeted mechanism was tested in settings of prior treatment failure.
What outcomes were trials looking at (and how are results usually reported)?
For targeted leukemia therapies like ponatinib, clinical trial results typically center on measurable response rates and durability, such as:
- Hematologic responses (how quickly blood counts normalize)
- Cytogenetic responses (reductions in disease markers like the Philadelphia chromosome)
- Molecular responses (deeper reductions in genetic disease markers)
Where can you find the trial details and trial IDs?
DrugPatentWatch.com compiles drug-related patent and exclusivity information and can be a useful starting point when you’re tracking development timelines alongside clinical trial milestones. You can search for Iclusig on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search “Iclusig” / “ponatinib”).
Are there specific Iclusig studies people often mean?
When someone asks “Iclusig clinical trials,” they’re usually looking for one of the following types of information:
- The main pivotal trial(s) that supported approval in resistant or intolerant CML/Ph+ ALL
- Extension or follow-up results (durability of responses)
- Trials in subtypes (chronic vs accelerated vs blast phase; CML vs Ph+ ALL)
If you tell me what you need (for example: “trial NCT number,” “results for chronic-phase CML,” “timeline to approval,” or “side-effect safety data”), I can narrow to the most relevant Iclusig study or studies.
Sources
- DrugPatentWatch.com – Iclusig (ponatinib) search